This study is not yet accepting patients
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Lawrence Fong, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Lawrence Fong, MD
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at the UCSF. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity Program in the Helen Diller Family Comprehensive Cancer Center.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- MedPacto, Inc.
- ID
- NCT04064190
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated